Antonia Maria Susanne Müller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonia Maria Susanne Müller has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Markus Gabriel Manz
Department of Medical Oncology and Hematology University Hospital Zurich and University of Zurich Zürich Switzerland
6 shared publications Markus G. Manz
Department of Medical Oncology and Hematology, University and University Hospital Zurich, Zurich, Switzerland
4 shared publicationsUrs Schanz
Department of Medical Oncology and Hematology University Hospital Zurich Zurich Switzerland
4 shared publicationsAlexander Ring
3 shared publicationsGayathri Nair
Department of Medical Oncology and Hematology University Hospital Zurich Zurich Switzerland
3 shared publicationsNicolas J. Mueller
Department of Infectious Diseases and Hospital Epidemiology University Hospital Zurich, University of Zürich Zürich Switzerland
3 shared publications
Latest Publications
- Open Access
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadt7366
A direct effect of the hematocrit on blood glucose: Evidence from hypoxia- and erythropoietin-treated mice
Blood glucose is lower in mountain dwellers living under low partial oxygen pressure. We show that obese mice maintained under hypoxia exhibit a delayed but distinct decrease in blood glucose with improved insulin sensitivity, which is independent of changes in body weight. This effect of hypoxia is mediated by erythropoiesis and is a direct result of the rising hematocrit, which could be due to erythrocytes acting as carriers of glucose units in the blood. Glucose lowering by the red cell mass is evidenced by a prompt decrease in glycemia in mice receiving a blood transfusion. Furthermore, life under hypoxia as well as treatment with erythropoietin reduce glycemia also in mice expressing the erythropoietin receptor exclusively in hematopoietic cells, which contrasts with previous assumptions attributing metabolic actions of erythropoietin to direct action on nonhematopoietic tissues. Our results provide a rationale for associations between hematocrit and blood glucose in humans under anti-anemic therapy, polycythemia, smoking, and high-altitude exposure.
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadt7366
Open AccessA direct effect of the hematocrit on blood glucose: Evidence from hypoxia- and erythropoietin-treated mice
Blood glucose is lower in mountain dwellers living under low partial oxygen pressure. We show that obese mice maintained under hypoxia exhibit a delayed but distinct decrease in blood glucose with improved insulin sensitivity, which is independent of changes in body weight. This effect of hypoxia is mediated by erythropoiesis and is a direct result of the rising hematocrit, which could be due to erythrocytes acting as carriers of glucose units in the blood. Glucose lowering by the red cell mass is evidenced by a prompt decrease in glycemia in mice receiving a blood transfusion. Furthermore, life under hypoxia as well as treatment with erythropoietin reduce glycemia also in mice expressing the erythropoietin receptor exclusively in hematopoietic cells, which contrasts with previous assumptions attributing metabolic actions of erythropoietin to direct action on nonhematopoietic tissues. Our results provide a rationale for associations between hematocrit and blood glucose in humans under anti-anemic therapy, polycythemia, smoking, and high-altitude exposure.
- Open Access
The cellular hierarchy of acute myeloid leukemia informs personalized treatment
Acute myeloid leukemia (AML) is characterized by malignant myeloid precursors that span a cellular hierarchy from dedifferentiated leukemic stem cells to mature blasts. While the diagnostic and prognostic importance of AML blast maturation is increasingly recognized, personalized therapies are currently not tailored to a patients individual makeup of this cellular hierarchy. In this study, we use multiplexed image-based ex vivo drug screening (pharmacoscopy) to systematically quantify the drug sensitivity across the cellular hierarchy of AML patients. We analyzed 174 prospective and longitudinal patient samples from 44 newly diagnosed AML patients, which indicated that differences in the AML hierarchy significantly identified poor responses to first-line therapy, outperforming European LeukemiaNet (ELN) criteria. Critically, drug response profiling across the AML hierarchy of each patient improved the accuracy of predicting patient response to first-line therapy (AUC 0.91), and revealed alternative individualized treatment options targeting the complete AML hierarchy of non-responding patients. We confirmed these findings in an independent cohort of 26 relapsed/refractory AML patients, for whom pan-hierarchy response profiling improved response predictions post hoc . Overall, our results quantify the clinical importance of therapeutically targeting the complete cellular hierarchy of newly diagnosed AML, and identify multiplexed image-based ex vivo drug screening to enable quantification and targeting of the AML maturation hierarchy for improved personalized treatment.
Open AccessThe cellular hierarchy of acute myeloid leukemia informs personalized treatment
Acute myeloid leukemia (AML) is characterized by malignant myeloid precursors that span a cellular hierarchy from dedifferentiated leukemic stem cells to mature blasts. While the diagnostic and prognostic importance of AML blast maturation is increasingly recognized, personalized therapies are currently not tailored to a patients individual makeup of this cellular hierarchy. In this study, we use multiplexed image-based ex vivo drug screening (pharmacoscopy) to systematically quantify the drug sensitivity across the cellular hierarchy of AML patients. We analyzed 174 prospective and longitudinal patient samples from 44 newly diagnosed AML patients, which indicated that differences in the AML hierarchy significantly identified poor responses to first-line therapy, outperforming European LeukemiaNet (ELN) criteria. Critically, drug response profiling across the AML hierarchy of each patient improved the accuracy of predicting patient response to first-line therapy (AUC 0.91), and revealed alternative individualized treatment options targeting the complete AML hierarchy of non-responding patients. We confirmed these findings in an independent cohort of 26 relapsed/refractory AML patients, for whom pan-hierarchy response profiling improved response predictions post hoc . Overall, our results quantify the clinical importance of therapeutically targeting the complete cellular hierarchy of newly diagnosed AML, and identify multiplexed image-based ex vivo drug screening to enable quantification and targeting of the AML maturation hierarchy for improved personalized treatment.
- Open Access
- 12 June 2024
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 20 (20) , 16-17
Readiness for Innovation and Pioneer Spirit
By Antonia Müller. This editorial from Prof. Dr Antonia Muller addresses the impact of CAR T-cell therapies in the cancer treatment landscape.
- 12 June 2024
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 20 (20) , 16-17
Open AccessReadiness for Innovation and Pioneer Spirit
By Antonia Müller. This editorial from Prof. Dr Antonia Muller addresses the impact of CAR T-cell therapies in the cancer treatment landscape.
- Open Access
- 12 June 2024
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 20 (20) , 26-33
Rare Toxicities of CAR T-Cell Therapy: Cardiovascular, Hematopoietic and Other Infrequent Adverse Events
Chimeric antigen receptor (CAR) T-cell therapy has proven to be an effective treatment option for various hematological malignancies. Despite the enormous potential of CAR T-cell therapy, there are still challenges to be addressed, including the management of significant toxicities associated with the treatment. The most frequent adverse events associated with CAR T-cell infusion are cytokine release syndrome (CRS), a systemic inflammatory response triggered by rapid CAR T-cell activation and expansion, and immune effector cell-associated neurotoxicity syndrome (ICANS) caused by peripheral immune overactivation, blood–brain barrier dysfunction, and central nervous system (CNS) inflammation. We recently reported on a spectrum of rare side effects of CAR T cells, specifically, toxicities caused by cellular infiltrations and local inflammation in critical sites and damage to neuronal structures or functions. This review article focuses on the less common toxicities of CAR T-cell products, including those related to cardiovascular and hematological complications, as well as other rare side effects. Efforts to understand the underlying mechanisms driving these toxicities and develop strategies to predict, prevent and manage them are crucial for optimizing the safety and efficacy of CAR T-cell therapy in clinical practice. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Dr Andreas Holbro, University Hospital Basel, Basel, Switzerland Prof. Dr Christoph Renner, Hospital Hirslanden, Zurich, Switzerland Prof. Dr Dr Dominik Schneidawind, University Hospital Zurich, Zurich, Switzerland Received: May 13, 2024; accepted after peer review: June 26, 2024.
- 12 June 2024
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 20 (20) , 26-33
Open AccessRare Toxicities of CAR T-Cell Therapy: Cardiovascular, Hematopoietic and Other Infrequent Adverse Events
Chimeric antigen receptor (CAR) T-cell therapy has proven to be an effective treatment option for various hematological malignancies. Despite the enormous potential of CAR T-cell therapy, there are still challenges to be addressed, including the management of significant toxicities associated with the treatment. The most frequent adverse events associated with CAR T-cell infusion are cytokine release syndrome (CRS), a systemic inflammatory response triggered by rapid CAR T-cell activation and expansion, and immune effector cell-associated neurotoxicity syndrome (ICANS) caused by peripheral immune overactivation, blood–brain barrier dysfunction, and central nervous system (CNS) inflammation. We recently reported on a spectrum of rare side effects of CAR T cells, specifically, toxicities caused by cellular infiltrations and local inflammation in critical sites and damage to neuronal structures or functions. This review article focuses on the less common toxicities of CAR T-cell products, including those related to cardiovascular and hematological complications, as well as other rare side effects. Efforts to understand the underlying mechanisms driving these toxicities and develop strategies to predict, prevent and manage them are crucial for optimizing the safety and efficacy of CAR T-cell therapy in clinical practice. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Dr Andreas Holbro, University Hospital Basel, Basel, Switzerland Prof. Dr Christoph Renner, Hospital Hirslanden, Zurich, Switzerland Prof. Dr Dr Dominik Schneidawind, University Hospital Zurich, Zurich, Switzerland Received: May 13, 2024; accepted after peer review: June 26, 2024.
- Open Access
- 26 March 2024
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 19 (19) , 42-49
Rare Adverse Events of CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment option for various types of cancers. Although it has shown remarkable effectiveness, this therapy is also associated with significant toxicity, which can limit its use. The most common adverse events associated with CAR T-cell infusion include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This review focuses on the less common toxicities of CAR T-cell products, including those related to cellular infiltration and inflammation in critical locations, toxicities affecting neuronal structures or functions and other rare side effects observed in clinical practice. PEER REVIEWED ARTICLE Peer reviewers: Prof. Dominik Schneidawind, University Hospital Zurich, Zurich, Switzerland. Dr Federico Simonetta, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. Received: February 13, 2024; Accepted after peer review: March 19, 2024
- 26 March 2024
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 19 (19) , 42-49
Open AccessRare Adverse Events of CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment option for various types of cancers. Although it has shown remarkable effectiveness, this therapy is also associated with significant toxicity, which can limit its use. The most common adverse events associated with CAR T-cell infusion include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This review focuses on the less common toxicities of CAR T-cell products, including those related to cellular infiltration and inflammation in critical locations, toxicities affecting neuronal structures or functions and other rare side effects observed in clinical practice. PEER REVIEWED ARTICLE Peer reviewers: Prof. Dominik Schneidawind, University Hospital Zurich, Zurich, Switzerland. Dr Federico Simonetta, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. Received: February 13, 2024; Accepted after peer review: March 19, 2024
- Open Access
- 14 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (8) , 2876
Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care Center
Background: Therapeutic plasma exchange (TPE) is frequently performed in critical care settings for heterogenous indications. However, specific intensive care unit (ICU) data regarding TPE indications, patient characteristics and technical details are sparse. Methods: We performed a retrospective, single-center study using data from January 2010 until August 2021 for patients treated with TPE in an ICU setting at the University Hospital Zurich. Data collected included patient characteristics and outcomes, ICU-specific parameters, as well as apheresis-specific technical parameters and complications. Results: We identified n = 105 patients receiving n = 408 TPEs for n = 24 indications during the study period. The most common was thrombotic microangiopathies (TMA) (38%), transplant-associated complications (16.3%) and vasculitis (14%). One-third of indications (35.2%) could not be classified according to ASFA. Anaphylaxis was the most common TPE-related complication (6.7%), while bleeding complications were rare (1%). The median duration of ICU stay was 8 ± 14 days. Ventilator support, renal replacement therapy or vasopressors were required in 59 (56.2%), 26 (24.8%), and 35 (33.3%) patients, respectively, and 6 (5.7%) patients required extracorporeal membrane oxygenation. The overall hospital survival rate was 88.6%. Conclusion: Our study provides valuable real-world data on heterogenous TPE indications for patients in the ICU setting, potentially supporting decision-making.
- 14 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (8) , 2876
Open AccessIndications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care Center
Background: Therapeutic plasma exchange (TPE) is frequently performed in critical care settings for heterogenous indications. However, specific intensive care unit (ICU) data regarding TPE indications, patient characteristics and technical details are sparse. Methods: We performed a retrospective, single-center study using data from January 2010 until August 2021 for patients treated with TPE in an ICU setting at the University Hospital Zurich. Data collected included patient characteristics and outcomes, ICU-specific parameters, as well as apheresis-specific technical parameters and complications. Results: We identified n = 105 patients receiving n = 408 TPEs for n = 24 indications during the study period. The most common was thrombotic microangiopathies (TMA) (38%), transplant-associated complications (16.3%) and vasculitis (14%). One-third of indications (35.2%) could not be classified according to ASFA. Anaphylaxis was the most common TPE-related complication (6.7%), while bleeding complications were rare (1%). The median duration of ICU stay was 8 ± 14 days. Ventilator support, renal replacement therapy or vasopressors were required in 59 (56.2%), 26 (24.8%), and 35 (33.3%) patients, respectively, and 6 (5.7%) patients required extracorporeal membrane oxygenation. The overall hospital survival rate was 88.6%. Conclusion: Our study provides valuable real-world data on heterogenous TPE indications for patients in the ICU setting, potentially supporting decision-making.
- Open Access
- 20 December 2022
- Published by Elsevier in JACC: Cardiooncology
- Vol. 4 (5) , 708-712
Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells
- 20 December 2022
- Published by Elsevier in JACC: Cardiooncology
- Vol. 4 (5) , 708-712
Open AccessFulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells
- Open Access
- 16 November 2022
- Published by Wiley in British Journal of Haematology
- Vol. 201 (1) , 58-63
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
Summary: Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients show impaired antibody (Ab) response to a standard two‐dose vaccination against severe acute respiratory syndrome coronavirus‐2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo‐HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo‐HCT recipients is critical to optimise current vaccination strategies.
- 16 November 2022
- Published by Wiley in British Journal of Haematology
- Vol. 201 (1) , 58-63
Open AccessAntibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
Summary: Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients show impaired antibody (Ab) response to a standard two‐dose vaccination against severe acute respiratory syndrome coronavirus‐2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo‐HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo‐HCT recipients is critical to optimise current vaccination strategies.
- Open Access
- 27 September 2022
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 13 (13) , 20-25
Long-Term Outcomes in Patients with Plasma Cell Myeloma Following High-Dose Chemotherapy with Autologous Stem Cell Transplantation
By Eva Oehlbaum, Alexander Ring & 2 more. The review article presents an overview of the association of patient- and treatment-related parameters with progression-free survival (PFS) and overall survival (OS) in PCM patients who underwent ASCT.
- 27 September 2022
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 13 (13) , 20-25
Open AccessLong-Term Outcomes in Patients with Plasma Cell Myeloma Following High-Dose Chemotherapy with Autologous Stem Cell Transplantation
By Eva Oehlbaum, Alexander Ring & 2 more. The review article presents an overview of the association of patient- and treatment-related parameters with progression-free survival (PFS) and overall survival (OS) in PCM patients who underwent ASCT.
- Open Access
- 19 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (18) , 10946
Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Autologous hematopoietic stem cell transplantation (aHSCT) is a highly efficient treatment of multiple sclerosis (MS), and hence it likely normalizes pathological and/or enhances beneficial processes in MS. The disease pathomechanisms include neuroinflammation, glial cell activation and neuronal damage. We studied biomarkers that in part reflect these, like markers for neuroinflammation (C-X-C motif chemokine ligand (CXCL) 9, CXCL10, CXCL13, and chitinase 3-like 1 (CHI3L1)), glial perturbations (glial fibrillary acidic protein (GFAP) and in part CHI3L1), and neurodegeneration (neurofilament light chain (NfL)) by enzyme-linked immunosorbent assays (ELISA) and single-molecule array assay (SIMOA) in the serum and cerebrospinal fluid (CSF) of 32 MS patients that underwent aHSCT. We sampled before and at 1, 3, 6, 12, 24 and 36 months after aHSCT for serum, as well as before and 24 months after aHSCT for CSF. We found a strong increase of serum CXCL10, NfL and GFAP one month after the transplantation, which normalized one and two years post-aHSCT. CXCL10 was particularly increased in patients that experienced reactivation of cytomegalovirus (CMV) infection, but not those with Epstein-Barr virus (EBV) reactivation. Furthermore, patients with CMV reactivation showed increased Th1 phenotype in effector memory CD4+ T cells. Changes of the other serum markers were more subtle with a trend for an increase in serum CXCL9 early post-aHSCT. In CSF, GFAP levels were increased 24 months after aHSCT, which may indicate sustained astroglia activation 24 months post-aHSCT. Other CSF markers remained largely stable. We conclude that MS-related biomarkers indicate neurotoxicity early after aHSCT that normalizes after one year while astrocyte activation appears increased beyond that, and increased serum CXCL10 likely does not reflect inflammation within the central nervous system (CNS) but rather occurs in the context of CMV reactivation or other infections post-aHSCT.
- 19 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (18) , 10946
Open AccessDynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Autologous hematopoietic stem cell transplantation (aHSCT) is a highly efficient treatment of multiple sclerosis (MS), and hence it likely normalizes pathological and/or enhances beneficial processes in MS. The disease pathomechanisms include neuroinflammation, glial cell activation and neuronal damage. We studied biomarkers that in part reflect these, like markers for neuroinflammation (C-X-C motif chemokine ligand (CXCL) 9, CXCL10, CXCL13, and chitinase 3-like 1 (CHI3L1)), glial perturbations (glial fibrillary acidic protein (GFAP) and in part CHI3L1), and neurodegeneration (neurofilament light chain (NfL)) by enzyme-linked immunosorbent assays (ELISA) and single-molecule array assay (SIMOA) in the serum and cerebrospinal fluid (CSF) of 32 MS patients that underwent aHSCT. We sampled before and at 1, 3, 6, 12, 24 and 36 months after aHSCT for serum, as well as before and 24 months after aHSCT for CSF. We found a strong increase of serum CXCL10, NfL and GFAP one month after the transplantation, which normalized one and two years post-aHSCT. CXCL10 was particularly increased in patients that experienced reactivation of cytomegalovirus (CMV) infection, but not those with Epstein-Barr virus (EBV) reactivation. Furthermore, patients with CMV reactivation showed increased Th1 phenotype in effector memory CD4+ T cells. Changes of the other serum markers were more subtle with a trend for an increase in serum CXCL9 early post-aHSCT. In CSF, GFAP levels were increased 24 months after aHSCT, which may indicate sustained astroglia activation 24 months post-aHSCT. Other CSF markers remained largely stable. We conclude that MS-related biomarkers indicate neurotoxicity early after aHSCT that normalizes after one year while astrocyte activation appears increased beyond that, and increased serum CXCL10 likely does not reflect inflammation within the central nervous system (CNS) but rather occurs in the context of CMV reactivation or other infections post-aHSCT.